1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Plasma Fractionation Market?
The projected CAGR is approximately 7.5%.
+1 2315155523
MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.
Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.
U.S. Plasma Fractionation MarketU.S. Plasma Fractionation Market by Product (Albumin, Immunoglobulin [Intravenous Immunoglobulin {IVIG}, Subcutaneous Immunoglobulin {SCIG}], Coagulation Factors [Factor IX, Factor VIII, Prothrombin Complex Concentrates, Fibrinogen Concentrates, Others], Protease Inhibitors, Others), by Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, Others), by End-user (Hospitals & Clinics, Clinical Research Laboratories, Others), by Forecast 2025-2033
The U.S. Plasma Fractionation Market size was valued at USD 15.64 USD Billion in 2023 and is projected to reach USD 25.95 USD Billion by 2032, exhibiting a CAGR of 7.5 % during the forecast period. Plasma fractionation is defined as the process of dividing or separating the plasma into its major elements for medicinal use. Common methods include cryoprecipitation, column chromatography, and precipitation with ethanol or other organic solvents. Some of the properties include: the ability to separate specific proteins such as albumin, immunoglobulins, and clotting factors, this helps in the purification of the protein to its highest point thus ensuring its effectiveness. Some of the example application areas include treatments for immune deficiency hemophilia and other blood disorders. In the US the market is shaped by technological innovation and a growing demand for plasma-derived products – the key market players focus on R&D investments to increase the yield and safety of plasma-derived therapies – this also indicates toward a robust growth trajectory.
Product:
Application:
End-user:
April 2023:
April 2023:
August 2021:
This comprehensive report offers an in-depth analysis of the U.S. plasma fractionation market, providing critical insights for stakeholders across the industry. The report goes beyond a simple overview, delivering actionable intelligence to inform strategic decision-making.
Our analysis encompasses:
This report is an invaluable resource for industry professionals, investors, and researchers seeking a comprehensive understanding of the U.S. plasma fractionation market.
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 7.5% from 2019-2033 |
| Segmentation |
|
Note*: In applicable scenarios
Primary Research
Secondary Research
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
The projected CAGR is approximately 7.5%.
Key companies in the market include CSL (Australia), Grifols, S.A. (Spain), Takeda Pharmaceutical Company Limited (Japan), Kedrion S.p.A (Italy), Octapharma AG (Switzerland), Bio Products Laboratory Ltd. (U.K.), LFB (France).
The market segments include Product, Application, End-user.
The market size is estimated to be USD 15.64 USD Billion as of 2022.
Rising Occurrence of Chronic Disorders to Propel the Market Growth.
Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.
Availability of Recombinant Therapies to Limit the Adoption of Plasma-Derived Therapies.
April 2023- CSL Behring received the U.S. FDA clearance for a prefilled syringe, Hizentra, a subcutaneous immunoglobulin (Human) intended for treating people suffering from Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.
The market size is provided in terms of value, measured in USD Billion.
Yes, the market keyword associated with the report is "U.S. Plasma Fractionation Market," which aids in identifying and referencing the specific market segment covered.
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
To stay informed about further developments, trends, and reports in the U.S. Plasma Fractionation Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.